Lyon University Hospital Launches Study on the Natural History of 7q11.23 Duplication Syndrome
Clinical Cohort of 15 Participants Established
France's Lyon University Hospital (Hospices Civils de Lyon) is initiating a natural history study (NCT07469566) involving 15 patients with 7q11.23 microduplication syndrome. Scheduled to begin in March 2026, this single-arm, non-blinded interventional study is in the exploratory phase, with no specific clinical trial phase assigned. Participants, aged over 5 and under 50, will be recruited from two institutions. Patients diagnosed via chromosomal microarray or qPCR will be compared to age-, sex-, and developmental-level-matched controls. While small, this represents a practical starting point for establishing a treatment-trial baseline for this rare disease, which has an estimated prevalence of 1 in 7,500 to 20,000.
Framework for Measuring Social Behavior Changes
The study will involve a single assessment of clinical, cognitive, adaptive, motor, and social evaluations, along with parent questionnaires and structural/functional brain magnetic resonance imaging (MRI) to reconstruct developmental trajectories. Key outcome measures include age of head control and independent sitting acquisition, the Vineland Adaptive Behavior Scales, 2nd Edition (VABS-2), the Autism Diagnostic Observation Schedule (ADOS) scores of 0-28, and the PDD-MRS scores of 0-19. Intelligence quotient, epilepsy, sensory profiles, and 24-hour activity/sleep data will be collected as secondary measures to dissect phenotypic heterogeneity. This data is crucial for defining age-specific patient selection criteria and responsive clinical endpoints for future drug trials.
Opportunity to Repurpose GTF2I-Targeted Therapies
The 7q11.23 region contains 26-28 genes, and overexpression of the transcription factor GTF2I has been implicated as a key driver of social and neurodevelopmental abnormalities. Studies of patient-derived neural cells have shown that histone deacetylase (HDAC) inhibitors, such as Zolinza and Vorinostat, can inhibit HDAC1, 2, 3, and 6, and reduce abnormal GTF2I expression. Mosetinostat and RG2833 have also been identified as potential candidates. The development stage of these three candidates for 7q11.23 indications is preclinical, and they will not be administered in this study. Vorinostat, marketed by Merck & Co. (MRK), was approved by the FDA on October 6, 2006, for cutaneous T-cell lymphoma, but this approval does not extend to this genetic disorder.
Competitive Landscape and Market Potential
Current standard of care includes speech, physical, and occupational therapy, cognitive behavioral therapy, and applied behavior analysis, as well as psychiatric medications for specific symptoms, with beta-blockers or surgery for aortic dilation. Therefore, the competitive landscape is less about competition between disease-modifying drugs and more about demonstrating improvement in social and functional outcomes compared to existing supportive therapies. While the direct indication market is rare, the broader market for autism spectrum disorder (ASD) treatments, of which it is a part, was valued at $2.11 billion in 2024. Validated natural history data that provides predictive endpoints and a therapeutic window could reduce the cost and development time for repurposing approved HDAC inhibitors.
This study, even with its limited sample size of 15, represents a significant step towards preparing for clinical trials in 7q11.23 duplication syndrome by combining ADOS, VABS-2, PDD-MRS, and MRI. From an investment perspective, it connects to the $2.11 billion ASD treatment market in 2024, but the rarity of the direct indication and the single-assessment design suggest that its value lies more in biomarker and endpoint development than in short-term commercial potential. For researchers, it provides a basis for linking GTF2I overexpression to social deficits and for translating preclinical-stage Vorinostat, Mosetinostat, and RG2833 into human trials. For the industry, it offers the option of repurposing Merck & Co. (MRK)'s marketed HDAC1, 2, 3, and 6 inhibitors, Zolinza and Vorinostat, but demonstrating clinical benefit over current standard therapies (speech therapy, behavioral therapy, etc.) and long-term neurotoxicity will be key to its long-term value.
Source: ClinicalTrials.gov (api_ct)